Remission in Asthma: What Is It? Can It Be Obtained? (AAN)

Price: FREE for members and non-members

Session recorded on November 12, 2024
Speaker: Michael S. Blaiss, MD, FACAAI

With the introduction of new therapies for asthma like biologics, achieving disease remission has become a new goal of treatment and classifying asthma control is in transition. In December 2023, the Annals of Allergy, Asthma & Immunology published a consensus statement between the American College of Allergy, Asthma & Immunology, American Academy of Allergy, Asthma, and Immunology, and American Thoracic Society to update the definition of clinical remission in asthma. In this webinar, learn more about the consensus statement and the outcomes of the working group. 

This program is a collaboration between the American College of Allergy, Asthma & Immunology and the Allergy and Asthma Network (AAN).

Explore other archived clinical webinars here.

Accreditation
The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation
The American College of Allergy, Asthma & Immunology (ACAAI) designates this enduring material for a maximum of 1 AMA PRA Category 1 CreditTM.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Target Audience

Primary Care Providers
Allied Health Professionals

Learning Objectives

Upon completion of this activity learners should be able to:
1. Explain the differences between asthma control and remission. 
2. Differentiate the definitions of remission in asthma.
3. Evaluate the basis for the Joint Consensus Statement of the ACAAI, AAAAI, and ATS on remission on treatment in asthma.

Additional information
Disclosure: 

As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma and Immunology (ACAAI) policy, all individuals in a position to control or influence the content of an activity must disclose all financial relationships with any ineligible company that have occurred within the past 24 months. 

Ineligible companies are those whose primary business is producing, marketing, selling, re-selling, or distributing health care products used by or on patients. The ACCME does not consider providers of clinical service directly to patients to be Ineligible Companies. Examples of ineligible companies include: 
 
•    Advertising, marketing, or communication firms whose clients are ineligible companies
•    Bio-medical startups that have begun a governmental regulatory approval process
•    Compounding pharmacies that manufacture proprietary compounds
•    Device manufacturers or distributors
•    Diagnostic labs that sell proprietary products
•    Growers, distributors, manufacturers or sellers of medical foods and dietary supplements
•    Manufacturers of health-related wearable products
•    Pharmaceutical companies or distributors
•    Pharmacy benefit managers
•    Reagent manufacturers or sellers
  
The ACCME does not consider providers of clinical service directly to patients to be commercial interests. For more information, visit www.accme.org. All identified relevant relationships must be mitigated and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure of or absence of relevant financial relationships be provided to the learners prior to the start of the activity.

Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials.

Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of the ACAAI. All identified relevant financial relationships with ineligible companies have been mitigated.

Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Attendance
Course opens: 
11/12/2024
Course expires: 
12/31/2025
Rating: 
0

All identified relevant financial relationships with ineligible companies have been mitigated.

Speaker:

Michael Blaiss, MD, FACAAI
Consultant: ALK, AstraZeneca, Bryn Pharma, SoundHealth, Hippo DX, Prollergy
Speaker: ALK, AstraZeneca, Regeneron, Sanofi
Advisor: GSK, Regeneron, Sanofi, Hippo DX, Prollergy, Nectar

Moderator:
Lynda Mitchell, Allergy Asthma Network (AAN)
No identified relevant finanical relationships with ineligible companies to disclose

Available Credit

  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Attendance
Please login or create an account to take this course.